Aligos Therapeutics Inc (ALGS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has a cash flow conversion efficiency ratio of -0.728x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.13 Million) by net assets ($31.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Aligos Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Aligos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aligos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aligos Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Aligos Therapeutics Inc (ALGS) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pioneer Motor Public Company Limited
BK:PIMO
|
0.043x |
|
Petratherm Ltd
AU:PTR
|
-0.044x |
|
Jade Marvel Group Bhd
KLSE:7043
|
0.010x |
|
Sun Race Sturmey-Archer Inc
TW:1526
|
0.044x |
|
Sangshin Electronics Co. Ltd
KQ:263810
|
-0.063x |
|
Harvard Bioscience Inc
NASDAQ:HBIO
|
0.044x |
|
TOP Engineering Co. Ltd
KQ:065130
|
0.098x |
|
IT Link
PA:ALITL
|
0.065x |
Annual Cash Flow Conversion Efficiency for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Aligos Therapeutics Inc from 2018 to 2025. View Aligos Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $53.55 Million | $-82.50 Million | -1.541x | -155.29% |
| 2024-12-31 | $-28.97 Million | $-80.74 Million | 2.787x | +424.84% |
| 2023-12-31 | $92.08 Million | $-79.00 Million | -0.858x | -12.28% |
| 2022-12-31 | $103.90 Million | $-79.39 Million | -0.764x | -22.04% |
| 2021-12-31 | $184.73 Million | $-115.66 Million | -0.626x | -85.51% |
| 2020-12-31 | $220.04 Million | $-74.26 Million | -0.337x | -146.83% |
| 2019-12-31 | $-64.89 Million | $-46.77 Million | 0.721x | +63.80% |
| 2018-12-31 | $-13.75 Million | $-6.05 Million | 0.440x | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more